Achieve has late-stage cytisinicline data, an accepted smoking-cessation NDA, and a fresh financing. The catch is that management now expects a manufacturing-driven FDA Complete Response Letter before any U.S. launch.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
